flecainide has been researched along with Myocardial Ischemia in 18 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "No evidence of ischemic heart disease was detected." | 5.30 | Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia. ( Ito, H; Nakamura, W; Segawa, K; Tanaka, S; Yoshimoto, N, 1998) |
| "In this study we investigated the time to the first arrhythmic, ischemic, or failure event for encainide-flecainide and moricizine versus their respective placebo comparison groups in the Cardiac Arrhythmia Suppression Trial." | 5.08 | Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. ( Anderson, JL; Carlson, M; Davies, R; Duff, HJ; Greene, HL; Hallstrom, AP; Huther, M; Kammerling, JM; Romhilt, DW, 1995) |
| "Flecainide may increase the incidence of cardiac arrhythmias in acute ischemia." | 3.69 | Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion. ( Ferrier, GR; Heisler, BE, 1996) |
| "Amiodarone has a more favourable therapeutic profile than flecainide and propafenone in these patients, having less tendency to worsen heart failure." | 2.67 | A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). ( , 1992) |
| "Flecainide was equi-effective at low and high concentrations, with VF incidence reduced from 92% to 17% (p < 0." | 1.31 | Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts. ( Curtis, MJ; Farkas, A, 2002) |
| "No evidence of ischemic heart disease was detected." | 1.30 | Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia. ( Ito, H; Nakamura, W; Segawa, K; Tanaka, S; Yoshimoto, N, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (66.67) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Plouvier, B | 1 |
| Beatch, GN | 1 |
| Jung, GL | 1 |
| Zolotoy, A | 1 |
| Sheng, T | 1 |
| Clohs, L | 1 |
| Barrett, TD | 2 |
| Fedida, D | 1 |
| Wang, WQ | 2 |
| Zhu, JJ | 1 |
| Liu, Y | 1 |
| Abraham, S | 1 |
| Lynn, L | 1 |
| Dong, Y | 1 |
| Wall, RA | 1 |
| Walker, MJ | 2 |
| Brisinda, D | 1 |
| Sorbo, AR | 1 |
| La Brocca, L | 1 |
| Fenici, R | 1 |
| Lip, GY | 1 |
| Fauchier, L | 1 |
| Freedman, SB | 1 |
| Van Gelder, I | 1 |
| Natale, A | 1 |
| Gianni, C | 1 |
| Nattel, S | 1 |
| Potpara, T | 1 |
| Rienstra, M | 1 |
| Tse, HF | 1 |
| Lane, DA | 1 |
| Belardinelli, L | 1 |
| Liu, G | 1 |
| Smith-Maxwell, C | 1 |
| El-Bizri, N | 1 |
| Hirakawa, R | 1 |
| Karpinski, S | 1 |
| Li, CH | 1 |
| Hu, L | 1 |
| Li, XJ | 1 |
| Crumb, W | 1 |
| Wu, L | 1 |
| Koltun, D | 1 |
| Zablocki, J | 1 |
| Yao, L | 1 |
| Dhalla, AK | 1 |
| Rajamani, S | 1 |
| Shryock, JC | 1 |
| Stramba-Badiale, M | 1 |
| Lazzarotti, M | 1 |
| Facchini, M | 1 |
| Schwartz, PJ | 1 |
| Hallstrom, AP | 1 |
| Anderson, JL | 1 |
| Carlson, M | 1 |
| Davies, R | 1 |
| Greene, HL | 1 |
| Kammerling, JM | 1 |
| Romhilt, DW | 1 |
| Duff, HJ | 1 |
| Huther, M | 1 |
| Aupetit, JF | 4 |
| Timour, Q | 4 |
| Larbre, JP | 1 |
| Loufoua-Moundanga, J | 3 |
| Kioueh, I | 3 |
| Lopez, M | 1 |
| Faucon, G | 3 |
| Liu, JX | 1 |
| Tanonaka, K | 1 |
| Ohtsuka, Y | 1 |
| Sakai, Y | 1 |
| Takeo, S | 1 |
| Greenberg, HM | 1 |
| Dwyer, EM | 1 |
| Hochman, JS | 1 |
| Steinberg, JS | 1 |
| Echt, DS | 1 |
| Peters, RW | 1 |
| Gout, B | 1 |
| Nichols, AJ | 1 |
| Feuerstein, GZ | 1 |
| Bril, A | 1 |
| Hayes, ES | 1 |
| Heisler, BE | 1 |
| Ferrier, GR | 1 |
| Nakamura, W | 1 |
| Segawa, K | 1 |
| Ito, H | 1 |
| Tanaka, S | 1 |
| Yoshimoto, N | 1 |
| Bui-Xuan, B | 1 |
| Loufoua, J | 1 |
| Frassati, D | 1 |
| Farkas, A | 1 |
| Curtis, MJ | 1 |
| Omar, S | 1 |
| Chevrel, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flecainide and Myocardial Ischemia
| Article | Year |
|---|---|
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
3 trials available for flecainide and Myocardial Ischemia
14 other studies available for flecainide and Myocardial Ischemia
| Article | Year |
|---|---|
Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; | 2007 |
Magnetocardiographic evaluation of nonarrhythmogenic flecainide-induced electrocardiographic T-wave inversion.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Diagnosis, Differential; Electrocardiography; Fe | 2017 |
A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiotonic | 2013 |
Malignant arrhythmias and acute myocardial ischemia: interaction between flecainide and the autonomic nervous system.
Topics: Animals; Autonomic Nervous System; Cardiac Complexes, Premature; Cats; Electrocardiography; Flecaini | 1994 |
Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia--study in the porcine in situ heart.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 1993 |
Improvement of ischemia/reperfusion-induced contractile dysfunction of perfused hearts by class Ic antiarrhythmic agents.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Creatine Kinase; Flecainide; Heart; Lidocai | 1993 |
Antifibrillatory effects of BRL-32872 in anesthetized Yucatan minipigs with regional myocardial ischemia.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Benzamides; Disease Models, Animal; Flecainid | 1995 |
Lack of selectivity for ventricular and ischaemic tissue limits the antiarrhythmic actions of lidocaine, quinidine and flecainide against ischaemia-induced arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Dose-Response Relationship, Drug; Electrocardiograp | 1995 |
Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Guinea Pigs; H | 1996 |
Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Coronary Vessels; Disopyramide; Electric Stimulatio | 1997 |
Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia.
Topics: Anti-Arrhythmia Agents; Diagnosis, Differential; Drug Therapy, Combination; Electrocardiography; Fle | 1998 |
Opposite change with ischaemia in the antifibrillatory effects of class I and class IV antiarrhythmic drugs resulting from the alteration in ion transmembrane exchanges related to depolarization.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Flecainide; Myocardial | 2000 |
Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Circulation; Electrocardiography; Fl | 2002 |
Role of asynchronous activation of the ventricular fibres by an ectopic pacemaker in the accidents, especially fibrillation, caused by Ic antiarrhythmic drugs.
Topics: Animals; Anti-Arrhythmia Agents; Female; Flecainide; Heart Conduction System; Male; Myocardial Ische | 1992 |